Disruption of endothelial cell interactions with the novel Hu177 cryptic collagen epitope inhibits angiogenesis

Clinical Cancer Research

Volumn 13, Issue 10, 2007, Pages 3068-3078

  Cretu, Alexandra ^a   Roth, Jennifer M ^a   Caunt, Maresa ^a   Akalu, Abebe ^a   Policarpio, Desiree ^a   Formenti, Silvia ^a   Gagne, Paul ^a   Liebes, Leonard ^a   Brooks, Peter C ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; EPITOPE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HU177; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ADHESION; CELL INTERACTION; CELL MIGRATION; CELL PROLIFERATION; CHICK EMBRYO; CONTROLLED STUDY; DRUG TARGETING; EMBRYO; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MELANOMA; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH;

ANIMALS; ANTIBODIES, MONOCLONAL; BIOLOGICAL ASSAY; CELL ADHESION; CELL PROLIFERATION; CHICK EMBRYO; COLLAGEN TYPE IV; CYCLIN-DEPENDENT KINASE INHIBITOR P27; ENDOTHELIUM, VASCULAR; EPITOPES; EXTRACELLULAR MATRIX; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; UP-REGULATION;

EID: 34249814899     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-2342     Document Type: Article

References (48)

1. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005;438:967-74.
2. Harper J, Moses MA. Molecular regulation of tumor angiogenesis: mechanisms and therapeutic implications. EXS 2006;96:223-68.
3. Gagne P, Akalua A, Brooks PC. Challenges facing antiangiogenic therapy for cancer: impact of the tumor extracellular environment. Expert Rev Anticancer Ther 2004;4:129-40.
4. Folkman J. Angiogenesis. Annu Rev Med 2006;57:1-18.
5. Zhou L, Isenberg JS, Cao Z, Roberts DD. Type I collagen is a molecular target for inhibition of angiogenesis by endogenous thrombospondin-1. Oncogene 2005;25:536-45.
6. Petitclerc E, Boutaud A, Prestayko A, et al. New functions for non-collagenous domains of human collagen type IV. Novel integrin ligands inhibiting angiogenesis and tumor growth in vivo. J Biol Chem 2000;275:8051-61.
7. Roth JM, Akalua A, Zelmanovich A, et al. Recombinant alpha 2(IV) NC1 domain inhibits tumor cell-extracellular matrix interactions, induces cellular senescence, and inhibits tumor growth in vivo. Am J Pathol 2005;166:901-11.
8. Davis GE, Senger DR. Endothelial extracellular matrix: biosynthesis, remodeling, and functions during vascular morphogenesis and neovessel stabilization. Circ Res 2005;97:1093-107.
9. Gustafsson E, Reinhard F. Insights into Extracellular matrix functions from mutant mouse models. Exp Cell Res 2000;26:52-68.
10. Vu TH, Shipley JM, Bergers G, et al. MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell 1998;93:411-22.
11. Zhou Z, Apte SS, Soininen R, et al. Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I. Proc Natl Acad Sci U S A 2000;97:4052-7.
12. Stickens D, Behonick DJ, Ortega N, et al. Altered endochondral bone development in matrix metalloproteinase 13-deficient mice. Development 2004;131:5883-95.
13. Fowlkes JL, Winkler MK. Exploring the interface between metallo-proteinase activity and growth factor and cytokine bioavailability. Cytokine Growth Factor Rev 2002;13:277-87.
14. Saksela O, Rifkin DB. Release of basic fibroblast growth factor-heparan sulfate complexes from endothelial cells by plasminogen activator-mediated proteolytic activity. J Cell Biol 1990;110:767-75.
15. Lee S, Jilani SM, Nikolova GV, Carpizo D, lruela-Arispe ML. Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J Cell Biol 2005;169:681-91.
16. van Hinsbergh VW, Engelse MA, Quax PH. Pericellular proteases in angiogenesis and vasculogenesis. Arterioscler Thromb Vasc Biol 2006;26:716-28.
17. Lakka SS, Gondi CS, Rao JS. Proteases and glioma angiogenesis. Brain Pathol 2005;15:327-41.
18. Xu J, Rodriguez D, Kim JJ, Brooks PC. Generation of monoclonal antibodies to cryptic collagen sites by using subtractive immunization. Hybridoma 2000;19:375-85.
19. Xu J, Rodriguez D, Petitclerc E, et al. Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo. J Cell Biol 2001;154:1069-79.
20. Hangai M, Kitaya N, Xu J, et al. Matrix metalloproteinase-9-dependent exposure of cryptic migratory control site in collagen is required before retinal angiogenesis. Am J Pathol 2002;161:1429-37.
21. Odaka C, Tanioka M, Itoh T. Matrix Metalloproteinase-9 in macrophages induces thymic neovascularization following thymocyte apoptosis. J Immunol 2005;174:846-53.
22. Brooks PC, Roth JM, Lymberis SC, DeWyngaert K, Broek D, Formenti SC. Ionizing radiation modulates the exposure of the HUIV26 cryptic epitope within collagen type IV during angiogenesis. Int J Radiat Oncol Biol Phys 2002;54:1194-19201.
23. Hotary KB, Allen ED, Brooks PC, Datta NS. Long MW, Weiss SJ. Membrane type I matrix metalloproteinase usurps tumor growth control imposed by the three-dimensional extracellular matrix. Cell 2003;114:33-45.
24. Filippov S, Koenig GC, Chun TH, et al. MT1-matrix metalloproteinase directs arterial wall invasion and neointima formation by vascular smooth muscle cells. J Exp Med 2005;202:663-71.
25. Lobov IB, Brooks PC, Lang RA. Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo. Proc Natl Acad Sci U S A 2002;99:11205-10.
26. Gagne PJ, Tihonov N, Li X, et al. Temporal exposure of cryptic collagen epitopes within ischemic muscle during hindlimb reperfusion. Am J Pathol 2005;1267:1349-59.
27. Petitclerc E, Stromblad S, von Schalscha TL, et al. Integrin alpha(v)beta3 promotes M21 melanoma growth in human skin by regulating tumor cell survival. Cancer Res 1999;59:2724-30.
28. Brooks PC, Montgomery AM, Rosenfeld M, et al. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994;79:1157-64.
29. Mu H, Ohashi R, Yan S, et al. Adipokine resistin promotes in vitro angiogenesis of human endothelial cells. Cardiovasc Res 2006;70:146-57.
30. Brooks PC, Montgomery AM, Cheresh DA. Use of the 10-day-old chick embryo for studying angiogenesis. Methods Mol Biol 1999;129:257-69.
31. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real time quantitative PCR and the 2-Delta Delta C(T) Method. Methods 2001;25:402-8.
32. Henriet P, Zhong ZD, Brooks PC, Weinberg KI, DeClerck YA. Contact with fibrillar collagen inhibits melanoma cell proliferation by up-regulating p27KIP1. Proc Natl Acad Sci U S A 2000;97:10026-31.
33. Bao W, Thullberg M, Zhang H, Onischenko A, Stromblad S. Cell attachment to the extracellular matrix induces proteasomal degradation of p21 (CIP1) via Cdc42/Rad signaling. Mol Cell Biol 2002;22:4587-97.
34. Stromblad S, Becker JC, Yebra M, Brooks PC, Cheresh DA. Suppression of p53 and p21WAF1/CIP1 expression by vascular cell integrin alphaVbeta3 during angiogenesis. J Clin Invest 1996;98:426-33.
35. Kase S, Yoshida K, Ohgami K, Shiratoni K, Harada T, Ohno S. Expression of (p27/KIP1) and cell proliferation in human retina and retinoblastoma. Anticancer Res 2005;25:3843-6.
36. Chantrain CF, Henriet P, Jodele S, et al. Mechanisms of pericyte recruitment in tumor angiogenesis: a new role for metalloproteinases. Eur J Cancer 2006;42:310-8.
37. Folgueras R, Pendas AM, Sanches LM, Lopez-otin C. Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies. Int J Dev Biol 2004;48:411-24.
38. Akalu A, Cretu A, Brooks PC. Targeting integrins for the control of tumour angiogenesis. Expert Opin Investig Drugs 2005;14:1475-86.
39. Lindsey ML, Escobar GP, Dobrucki LW, et al. Matrix metalloproteinase-9 gene deletion facilitates angiogenesis after myocardial infraction. Am J Physiol Heart Circ Physiol 2006;290:H232-9.
40. Pozzi A, Moberg PE, Miles LA, Wagner S, Soloway P, Gardner HA. Elevated matrix metalloproteinase and angiostatin levels in integrin alpha 1 knockout mice cause reduced tumor vascularization. Proc Natl Acad Sci USA 2000;97:2202-7.
41. Jones JI, Gockerman A, Busby WH, Jr., Camacho-Hubner C, Clemmons DR. Extracellular matrix contains insulin-like growth factor binding protein-5: potentiation of the effects of IGF-I. J Cell Biol 1993;121:679-87.
42. Nyberg P, Xie L, Kalluri R. Endogenous inhibitors of angiogenesis. Cancer Res 2005;65:3967-79.
43. Wang B, Sun J, Kitamoto S, et al. Cathepsin S controls angiogenesis and tumor growth via matrix-derived angiogenic factors. J Biol Chem 2006;281:6020-9.
44. Giannelli G, Falk Marzillier J, Schiraldi O, Stetler-Stevension WG, Quaranta V. Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. Science 1997;277:225-8.
45. Watanabe K, Takahashi H, Habu Y, et al. Interaction with heparin and matrix metalloproteinase 2 cleavage expose a cryptic anti-adhesive site of fibronectin. Biochemistry 2000;39:7138-44.
46. Khan FKM, Laurie GW, McCaffrey TA, Falcone DJ. Exposure of cryptic domains in the α1-chain of laminin-1 by elastase stimulates macrophages urokinase and matrix metalloproteinase-9 expression. J Biol Chem 2002;227:13778-86.
47. Roth JM, Caunt M, Cretu, et al. Inhibition of experimental metastasis by targeting the HUIV26 cryptic epitope in collagen. Am J Pathol 2006;168:1576-86.
48. kip 1 in thyroid cancer cells by PI3K/AKT pathway. Am J Pathol 2005;166:737-49.